IRIS
NUVOLONE, MARIO ULISSE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.411
AS - Asia 2.787
EU - Europa 1.784
SA - Sud America 429
AF - Africa 176
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 2
Totale 8.595
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.320
CN - Cina 1.027
SG - Singapore 690
IE - Irlanda 510
HK - Hong Kong 372
VN - Vietnam 341
BR - Brasile 322
RU - Federazione Russa 271
DE - Germania 210
FI - Finlandia 155
IT - Italia 152
FR - Francia 142
ZA - Sudafrica 141
GB - Regno Unito 89
IN - India 70
BD - Bangladesh 65
UA - Ucraina 60
CA - Canada 47
AR - Argentina 42
MX - Messico 30
IQ - Iraq 29
SE - Svezia 29
ES - Italia 26
PL - Polonia 26
JP - Giappone 24
TR - Turchia 23
NL - Olanda 18
AT - Austria 17
PK - Pakistan 17
BE - Belgio 16
CO - Colombia 16
SA - Arabia Saudita 15
ID - Indonesia 14
EC - Ecuador 13
LT - Lituania 11
VE - Venezuela 10
JO - Giordania 9
LB - Libano 9
PH - Filippine 9
UZ - Uzbekistan 9
MA - Marocco 8
UY - Uruguay 7
AE - Emirati Arabi Uniti 6
AL - Albania 6
CH - Svizzera 6
CL - Cile 6
EG - Egitto 6
MY - Malesia 6
PY - Paraguay 6
TN - Tunisia 6
AU - Australia 5
AZ - Azerbaigian 5
BG - Bulgaria 5
JM - Giamaica 5
KE - Kenya 5
PT - Portogallo 5
TH - Thailandia 5
IR - Iran 4
KR - Corea 4
NO - Norvegia 4
AM - Armenia 3
BH - Bahrain 3
BN - Brunei Darussalam 3
BO - Bolivia 3
CZ - Repubblica Ceca 3
HN - Honduras 3
HR - Croazia 3
IL - Israele 3
PE - Perù 3
CY - Cipro 2
DK - Danimarca 2
GA - Gabon 2
GE - Georgia 2
GR - Grecia 2
KZ - Kazakistan 2
LU - Lussemburgo 2
LV - Lettonia 2
MK - Macedonia 2
MN - Mongolia 2
MU - Mauritius 2
NG - Nigeria 2
NP - Nepal 2
QA - Qatar 2
RO - Romania 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
AF - Afghanistan, Repubblica islamica di 1
AO - Angola 1
BB - Barbados 1
BY - Bielorussia 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
ET - Etiopia 1
EU - Europa 1
GT - Guatemala 1
IS - Islanda 1
KG - Kirghizistan 1
KW - Kuwait 1
LK - Sri Lanka 1
LY - Libia 1
Totale 8.581
Salva come PNG Salva come JPEG
Città #
Dublin 510
San Jose 465
Singapore 379
Hong Kong 361
Chandler 349
Ashburn 342
Dallas 278
Beijing 245
Nanjing 158
Boardman 138
Johannesburg 128
Los Angeles 111
Ho Chi Minh City 104
Lauterbourg 101
Helsinki 96
Jacksonville 94
Hanoi 93
Council Bluffs 77
New York 73
Princeton 73
Lawrence 68
Munich 58
Wilmington 57
Medford 53
Nanchang 53
Ann Arbor 52
Buffalo 50
Redondo Beach 49
Shanghai 48
Shenyang 42
São Paulo 42
Orem 39
Jiaxing 38
Moscow 36
Hebei 35
Changsha 34
Pavia 34
Hangzhou 31
Milan 27
Santa Clara 25
Tianjin 24
Tokyo 23
Warsaw 23
Frankfurt am Main 22
Denver 20
Da Nang 19
London 19
Montreal 18
Nuremberg 18
The Dalles 18
Haiphong 17
Poplar 16
San Francisco 16
Turku 16
Woodbridge 16
Brussels 15
Norwalk 15
Redwood City 15
Seattle 15
Toronto 15
Atlanta 14
Chennai 14
Falkenstein 14
Mexico City 14
Piscataway 13
Brooklyn 12
Chicago 12
Ankara 11
Stockholm 11
Baghdad 10
Amman 9
Amsterdam 9
Belo Horizonte 9
Fairfield 9
Houston 9
Hải Dương 9
Phoenix 9
Rio de Janeiro 9
Washington 9
Biên Hòa 8
Brasília 8
Charlotte 8
Riyadh 8
Beirut 7
City of London 7
Curitiba 7
Guangzhou 7
Hyderabad 7
Manchester 7
Rome 7
Vienna 7
Boston 6
Jeddah 6
Manaus 6
Medellín 6
Montevideo 6
Paris 6
Tamm 6
Tashkent 6
Zhengzhou 6
Totale 5.754
Salva come PNG Salva come JPEG
Nome #
A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis 152
An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis 133
Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays 126
Amyloid Diseases at the Molecular Level: General Overview and Focus on AL Amyloidosis 123
Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients 122
Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis 122
ATR-FTIR spectroscopy supported by multivariate analysis for the characterization of adipose tissue aspirates from patients affected by systemic amyloidosis 121
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 121
Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis 119
Bone marrow amyloidosis. 118
Patterns of relapse after upfront bortezomib therapy in AL amyloidosis 116
Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide 113
Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine 112
Identification of genes for normalization of RT-qPCR gene expression data: A review of published literature 111
Bone marrow microenvironment in light-chain amyloidosis: In vitro expansion and characterization of mesenchymal stromal cells 111
Single-molecule real-time sequencing of the M protein: Toward personalized medicine in monoclonal gammopathies 110
Prognostication of survival and progression to dialysis in AA amyloidosis 109
Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib and thalidomide 108
Correlation between serum concentrations of N-terminal natriuretic peptide type B (NT-proBNP) and troponin-I (TnI) in AL amyloidosis 108
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 106
A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis 104
Altered monoaminergic systems and depressive-like behavior in congenic prion protein knock-out mice 104
Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis 102
Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response 101
Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis:insights into the timing of proteolysis 101
Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis 100
Daratumumab in light chain deposition disease: Rapid and profound hematologic response preserves kidney function 100
Prospective urinary albumin/creatinine ratio for diagnosis, staging, and organ response assessment in renal AL amyloidosis: Results from a large cohort of patients 98
A complicated evaluation of the response to the therapy in a patient with light chain deposition disease 97
Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome 95
Analysis of cyclin D1 mRNA expression levels in plasma cell dyscrasias: A systematic review of published literature 92
A case of monoclonal gammopathy of renal significance 92
Amyloid diseases at the molecular level: general overview and focus on AL amyloidosis. 91
Regulated expression of amyloidogenic immunoglobulin light chains in mice 91
Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy 90
Helical superstructures between amyloid and collagen in cardiac fibrils from a patient with AL amyloidosis 89
A nationwide prospective registry of bortezomib-based therapy in light chain (AL) amyloidosis 89
Liver involvement as the hallmark of aggressive disease in light chain amyloidosis: distinctive clinical features and role of light chain type in 225 patients 85
High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate 85
Development and Validation of Staging Systems for AA Amyloidosis 84
Cystatin F is a biomarker of prion pathogenesis in mice 83
Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: Prospective study in 206 patients 83
Cells and prions: A license to replicate 80
Clonal biomarkers for diagnosis and response to treatment assessment in light chain amyloidosis: The role of the laboratory 79
Prion protein and Ab-related synaptic toxicity impairment 79
Extended characterization of the novel co-isogenic C57BL/6J Prnp−/− mouse line 79
Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis 78
Protease-sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation 78
Treating Protein Misfolding Diseases: Therapeutic Successes Against Systemic Amyloidoses 77
Emerging therapeutic targets currently under investigation for the treatment of systemic amyloidosis 77
The prion protein is an agonistic ligand of the G protein-coupled receptor Adgrg6 76
Genome-wide transcriptomics identifies an early preclinical signature of prion infection 76
The Cryo-EM STRUCTURE of Renal Amyloid Fibril Suggests Structurally Homogeneous Multiorgan Aggregation in AL Amyloidosis 75
Cryo-EM structure of ex vivo fibrils associated with extreme AA amyloidosis prevalence in a cat shelter 75
A neuroprotective role for microglia in prion diseases 75
Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach 74
Prion pathogenesis in the absence of NLRP3/ASC inflammasomes 74
Efficient amyloid A clearance in the absence of immunoglobulins and complement factors 74
The complex PrPc-Fyn couples human oligomeric Aβ with pathological tau changes in Alzheimer's disease 74
Expanding the spectrum of systemic amyloid diseases: a new hint from the kidney 72
Efficient generation of multipotent mesenchymal stem cells from umbilical cord blood in stroma-free liquid culture 72
Oral Therapy for the Treatment of Transthyretin-Related Amyloid Cardiomyopathy 70
A safety review of drug treatments for patients with systemic immunoglobulin light chain (AL) amyloidosis 70
Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development 69
Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis 69
Structure-based drug design identifies polythiophenes as antiprion compounds 69
A Strategy for the Selection of RT-qPCR Reference Genes Based on Publicly Available Transcriptomic Datasets 67
Nanobodies counteract the toxicity of an amyloidogenic light chain by stabilizing a partially open dimeric conformation 66
Delayed identification of monoclonal protein is associated with early death in isolated cardiac AL amyloidosis 65
Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis 65
Prion pathogenesis is unaltered in a mouse strain with a permeable blood-brain barrier 65
Brain aging is faithfully modelled in organotypic brain slices and accelerated by prions 64
Free light measurement identifies relapse and prompts to reconsider amyloid typing in a patient with AL amyloidosis 62
The Role of the NADPH Oxidase NOX2 in Prion Pathogenesis 61
Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival 60
Novel challenges in the management of immunoglobulin light chain amyloidosis: from the bench to the bedside 60
Diagnostic Performance of the New Free Light Chain Ratio in Systemic Amyloidosis 59
Strictly co-isogenic C57BL/6J-Prnp-/- mice: A rigorous resource for prion science 59
Prion pathogenesis is unaltered in the absence of SIRPα-mediated "don't-eat-me" signaling 59
The workings of the amyloid diseases. 59
Prion diseases disrupt glutamate/glutamine metabolism in skeletal muscle 57
Systemic amyloidosis: novel therapies and role of biomarkers 57
Improved outcomes for kidney transplantation in AL amyloidosis: impact on practice 57
Analysis of co-isogenic prion protein deficient mice reveals behavioral deficits, learning impairment, and enhanced hippocampal excitability 57
The Priority position paper: Protecting Europe's food chain from prions 55
Evaluation of response to treatment in a patient with light chain amyloidosis and low free light chain burden 54
Author Correction: The dengue-specific immune response and antibody identification with machine learning 53
Daratumumab-based regimens versus CyBorD in newly diagnosed patients with AL amyloidosis and IIIb cardiac stage: A matched case-control study 52
The ASC inflammasome adapter governs SAA-derived protein aggregation in inflammatory amyloidosis 52
SIRPα polymorphisms, but not the prion protein, control phagocytosis of apoptotic cells 52
SMaRT M-Seq: an optimized step-by-step protocol for M protein sequencing in monoclonal gammopathies 51
Management of the elderly patient with AL amyloidosis 50
Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients 50
The immunobiology of prion diseases 49
Tau Exon 10 Inclusion by PrPC through Downregulating GSK3β Activity 48
The Interaction of the Tumor Suppressor FAM46C with p62 and FNDC3 Proteins Integrates Protein and Secretory Homeostasis 48
Glial activation in prion diseases is selectively triggered by neuronal PrPSc 47
TENT5C/FAM46C modulation in vivo reveals a trade-off between antibody secretion and tumor growth in multiple myeloma 45
Lymphocyte activation gene 3 (Lag3) expression is increased in prion infections but does not modify disease progression 45
Redirecting proteoxicity 45
Totale 8.103
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.717
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.717
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212 0 0 0 0 0 0 0 0 0 0 0 2
2021/2022280 3 5 3 0 8 9 6 26 20 5 40 155
2022/20231.175 119 89 20 66 92 104 25 51 563 6 29 11
2023/2024471 59 103 25 28 46 102 16 26 6 18 22 20
2024/20251.541 28 110 12 37 17 119 94 97 401 69 187 370
2025/20264.328 283 271 371 507 606 157 795 271 472 284 134 177
Totale 8.797